Due to technical maintenance the webshop is closed until January 3, 4. We wish you a successful 2024!
LEIDEN 30th March, 2023 - BIOKÉ announced it has signed a distribution agreement with Telesis Bio to distribute their technology in the Netherlands, Belgium, and Luxembourg (Benelux), effective immediately.
Telesis Bio is revolutionizing the synthetic biology landscape, enabling researchers to accelerate the development of innovative solutions to address some of the most pressing challenges facing humanity. Through our expertise in DNA biology and breakthrough automation solutions for biological synthesis, we empower rapid, accurate, and reproducible writing of DNA and mRNA for a wide range of biological applications. Telesis’ technology is being adopted by researchers worldwide, helping to overcome current bottlenecks in synthetic biology workflows and drive the discovery of cutting-edge solutions in fields such as health and technology. They are proud to collaborate with premier academic research institutions, emerging startups, and nearly all of the Top 25 Biopharma companies. Telesis Bio has played a role in several pioneering advances of our customers and collaborators, ranging from novel infectious disease vaccines, precision immunotherapy for cancer, and antibody therapeutics to the creation of engineered meat substitutes and sustainable cellular agricultural products. We are honored to be part of these groundbreaking achievements.
"Telesis Bio and BIOKÉ are ideal partners due to their shared values and goals. Telesis Bio's team of diverse scientists, engineers, and thinkers are dedicated to making synthetic biology more accessible to researchers worldwide, while BIOKÉ is committed to delivering high-quality research and diagnostic products that accelerate biological understanding and enable personalized medicine”, says Koos Kranenborg, General Manager BIOKÉ. “Telesis Bio's pioneering advances in the field of synthetic biology, including the industry-standard Gibson Assembly method® and the BioXp™ 3250 synthetic biology workstation, complement BIOKÉ's expertise in developing high-quality research and diagnostic products,” says Robert Hovingh, Sales Manager BIOKÉ.
“Together, we can offer researchers a comprehensive suite of tools and solutions to support their work and accelerate breakthroughs in fields such as personalized medicine and sustainable agriculture. With their shared values and goals, Telesis Bio and BIOKÉ are poised to make a significant impact in the world of synthetic biology and beyond.” says Todd R. Nelson, PhD President, Chief Executive Officer of Telesis Bio.
Learn more about Telesis Bio
Telesis Bio, previously known as Codex DNA, specializes in synthetic biology with a primary focus on empowering researchers to construct or synthesize artificial deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA). By addressing bottlenecks in the multi-step process of creating DNA and mRNA, and overcoming limitations of current solutions that restrict production at a usable scale, Telesis Bio's synthetic biology solution provides a comprehensive approach. The company's BioXp system is an end-to-end automated workstation that streamlines the process. Telesis Bio's product portfolio includes BioXp systems such as the BioXp 3250 system, BioXp kits that facilitate the generation of synthetic DNA and mRNA, as well as benchtop reagents that complement the automated synthetic biology workflow applications and solutions. The company has launched eight BioXp kits, three benchtop reagent kits, and various other synthetic biology products, including 14 SARS-CoV-2 full-length genomes and RNA controls, and its Vmax X2 cells. With approximately 200 BioXp systems installed globally, Telesis Bio is making a significant impact in the synthetic biology field.
For additional information, visit telesisbio.com.
Founded in 2004, BIOKÉ is an experienced and knowledgeable company that provides innovative products with the highest quality in the life science industry throughout Europe. BIOKÉ delivers unique and high-performance products for genomics, protein analysis and cell biology. In July 2009 Cell Signaling Technology, Inc. (CST) acquired BIOKÉ BV and BIOKÉ became a business unit of Cell Signaling Technology Europe. CST Europe and BIOKÉ hold offices in Leiden, the Netherlands. For additional information please visit the website at bioke.com.